Therapeutic Antibodies

#Antibodies #Clinical trials #Covid-19

NIH study aims to identify promising COVID-19 treatments for larger clinical trials

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial,… Read More

#Covid-19 #News

#Antibodies #Biologics / Biotechnology #Biopharma

Bristol Myers Squibb licences IONTAS’ mammalian display technology

IONTAS, a biotechnology company focused on antibody discovery technology development, has entered into a licensing agreement with Bristol Myers Squibb regarding its proprietary mammalian display. Under the terms of this agreement, IONTAS will receive an upfront payment for accessing the technology platform and will work with Bristol Myers Squibb in… Read More

#News

#Antibodies #Covid-19 #NIAID

Genetic and immunologic reasons explain severe COVID-19 cases

New findings by scientists at the National Institutes of Health and their collaborators help explain why some people with COVID-19 develop severe disease. The findings also may provide the first molecular explanation for why more men than women die from COVID-19. The researchers found that more than 10% of people… Read More

#Covid-19

#Biologics #Drug development #Erythropoietin #Gene therapy #SCIEX

The power of precision to keep biologics safe and effective

How do we know the medicines we take are safe and effective from batch to batch? Medicinal products like erythropoietin and gene therapies can be very challenging to quality control. Dr Mark Lies, Global Business Manager of Capillary Electrophoresis, SCIEX describes how capillary electrophoresis is being applied to address these… Read More

#Exclusive Content